Disease model cell services combining iPS cell technology and genome editing technology

「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」

「The company has expanded its business centered on iPS cell services, including gene modification services launched in 2018, iPS cell production services and various differentiation-induction services.」

「The company has expanded its business centered on iPS cell services, including gene modification services launched in 2018, iPS cell production services and various differentiation-induction services.」

「As a new business in research support, we began providing disease-model cell production services using gene-modification technology in collaboration with GenAhead Bio, an investee company of the Company, in October 2018. GenAhead Bio is a team of genome-editing specialists with proprietary "SNIPER" technology enabling highly accurate and efficient genome editing.」

「As a new business within its research support business, the company will jointly develop a disease-model cell production service using gene modification technology with its investee GenAhead Bio. The company is a team of genome-editing specialists and owns proprietary technology called SNIPER, which enables highly accurate and efficient genome editing.」

「The company made a strategic investment in GenAhead Bio, which owns proprietary, advanced gene-editing technology. It plans to launch a new service for producing disease-model cells by combining the group's human iPS cell production technology with world-leading genome-editing technology. Through this initiative, the company will further differentiate itself from competitors.」